CASI Pharmaceuticals, Inc.
CASIF
$0.10
$0.00-2.38%
OTC PK
| 12/31/2025 | 09/30/2025 | 03/31/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | 8.39% | 8.39% | -15.77% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | 8.39% | 8.39% | -15.77% |
| Cost of Revenue | -- | -- | 52.75% | 52.75% | 25.78% |
| Gross Profit | -- | -- | -23.27% | -23.27% | -44.41% |
| SG&A Expenses | -- | -- | 10.16% | 10.16% | -0.94% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | 99.89% | 99.89% | 99.97% |
| Total Operating Expenses | -- | -- | 27.46% | 27.46% | 14.52% |
| Operating Income | -- | -- | -47.74% | -47.74% | -55.11% |
| Income Before Tax | -- | -- | -34.76% | -34.76% | -49.04% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -- | -- | -35.13% | -35.13% | -49.50% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | -- | -32.91% | -32.91% | -45.73% |
| EBIT | -- | -- | -47.74% | -47.74% | -55.11% |
| EBITDA | -- | -- | -54.02% | -54.02% | -59.01% |
| EPS Basic | -- | -- | -10.01% | -10.01% | -25.16% |
| Normalized Basic EPS | -- | -- | -25.30% | -25.30% | -43.45% |
| EPS Diluted | -- | -- | -9.94% | -9.94% | -25.06% |
| Normalized Diluted EPS | -- | -- | -25.30% | -25.30% | -43.45% |
| Average Basic Shares Outstanding | -- | -- | 18.65% | 18.65% | 14.80% |
| Average Diluted Shares Outstanding | -- | -- | 18.65% | 18.65% | 14.80% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |